Streetwise Articles


News Update

Life Science Company Addresses Antibiotic Resistance Problem

News Update
  ()
This firm's proprietary technology provides an alternative to antibiotic use in livestock production. read more >
News Update

Biotech Files Patent Application for Nitric Oxide Delivery Device

News Update
  ()
With this development, the company advances blood/plasma transfusion technology. read more >

Imprimis: Priming the Pumps for a Big 2019

Contributed Opinion
  ()
Daniel Carlson of Tailwinds Research profiles a biotech company he is bullish on. read more >

Catalysts Approaching for U.S. Developer of Cancer Therapeutics

Research Report
  ()
An H.C. Wainwright & Co. report highlighted this biotech's upcoming key events to watch. read more >

Biotech Announces Preclinical Data on its Intravaginal Rings at Meeting

Research Report
  ()
A ROTH Capital Partners report relayed the contents of both presented abstracts. read more >

Target Price Raised on Biotech in Anticipation of Clinical Trial Presentation

Research Report
  ()
An H.C. Wainwright & Co. report discussed what investors might expect to hear from the company regarding its cholesterol-lowering therapy. read more >
News Update

Selectively Targeting Alzheimer's Disease's Root Cause Is Key, Biotech Says

News Update
  ()
This firm explains how its 15 years in drug development led to and supports this conclusion. read more >
News Update

Coverage Initiated on Developer of Targeted Gene Therapies for Cancer

Research Report
  ()
A LifeSci Capital report highlighted the advantages of this biotech story's lead candidate targeting bladder cancer. read more >

Hemp Sales Grow at CV Sciences: Q3 Beats Estimates, 2019 Outlook

Contributed Opinion
  ()
Fincom Investment Partners takes a look at Q3 earnings for a U.S.-based CBD company and explains why it believes it offers good value. read more >

A Canadian Cannabis Company for the Next Wave

Contributed Opinion
  ()
Ron Struthers, who believes the ideal marijuana stock to buy at this time is one that is focused on cannabis oil, profiles one such company that he sees as undervalued. read more >

Biotech’s Lead Drug Candidate Targets 'Market with Huge Potential'

Research Report
  ()
A ROTH Capital Partners report outlines its reasons for initiating coverage on this epigenetic therapeutics developer, whose lead candidate is in trials in diabetes, end-stage renal disease and other indications. read more >
News Update

Biotech Pinpoints Third Set of Targets for Potential Alzheimer's Treatment

News Update
  ()
With this achievement, the firm expands its potential partnering opportunities. read more >

Three Small-Caps on This Fund Manager's List

  ()
Steve Palmer, founding partner, President and Chief Investment Officer of AlphaNorth Asset Management, talks with Streetwise Reports about several small-cap companies from three sectors that he has been following. read more >

Update on Stock in Vanguard of Drive to Phase Out Antibiotics in Animal Feed

Contributed Opinion
  ()
Technical analyst Clive Maund provides an update on a company whose product is replacing antibiotics for growth promotion in animal feed. read more >

This Biotech, Whose Discovery Could End Routine Antibiotic Use in Livestock, Is the Pick of Three Fund Managers

  ()
Multiple governments around the world have unleashed mandates on livestock feed regulations that pose an opportunity for a Canada-based biotech company. read more >

As Anixa Starts Approaching the FDA, We Discuss Its Two Innovative Programs

Contributed Opinion
  ()
Dr. Amit Kumar, CEO of Anixa Biosciences, sits down with Daniel Carlson of Tailwinds Research to discuss the company's trials of CAR-T for solid tumors, as well as its Cchek program to distinguish between benign conditions and malignant cancer. read more >

Catasys…Future's So Bright

Contributed Opinion
  ()
Daniel Carlson of Tailwinds Research discusses a company that helps health plans solve the hidden, high-cost problem of untreated behavioral health conditions. read more >

Biotech to Expand Precision Medicine Services via New Partnership

Research Report
  ()
A Maxim Group report discussed the potential implications of this new collaboration in the field of personalized medicine and oncology. read more >

Hemp Producer CV Sciences' Q3 Earnings Estimates--Our View

Contributed Opinion
  ()
Fincom Investment Partners previews Q3 earnings estimates for a company that it believes offers the best value in cannabis/hemp. read more >
News Update

Animal Health Product Developer to Expand Sales Footprint

News Update
  ()
This Canadian company makes progress with its commercial uptake efforts. read more >

Biotech Advances Monoclonal Antibody Technology and Is Awarded Gates Foundation Grant

Research Report
  ()
An H.C. Wainwright & Co. report delivered the latest news regarding one of this immunotherapy firm's platforms, including the receipt of the first-ever U.S. patents for DNA-encoded monoclonal antibody technology. read more >
News Update

Innovative Cannabis Product Developer Achieves Two Stock Trading Milestones

News Update
  ()
This company now trades on both U.S. and Canadian stock exchanges. read more >

Biotech Reports Encouraging Interim Gene Therapy Data for Skin Disorder

Research Report
  ()
This company's findings to date for its topical therapy candidate have encouraging implications for an orphan indication. read more >

Groundbreaking Biotech Company Takes Major Step Forward with Deal with Chinese Partner

  ()
Canada-based biotech company signs major deal with Chinese partner to advance groundbreaking technology in the skin and tendon rejuvenation space. read more >
News Update

Tech Firm Launches Medical Cannabis User Data App, Lands Partnership

News Update
  ()
This "patient-care solution" is designed to help retailers make product recommendations. read more >
Showing Results: 1 to 25 of 89 Next

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"PMN is looking to outlicense PMN310 after the Phase 1 study." ❭
– André Uddin, Mackie Research Capital
"DRRX intends to start a NASH trial as soon as H1/19." ❭
– Francois Brisebois, Laidlaw & Company
"VIVs recent distribution deals illustrate demand for its technology." ❭
– Alex Koyfman, First Call